Optimizing First-Line Therapy for Follicular Lymphoma: Is It Time for Chemotherapy-Free Approaches?

Richard I. Fisher

doi:10.6004/jnccn.2019.5038

Jump to Content

Optimizing First-Line Therapy for Follicular Lymphoma: Is It Time for Chemotherapy-Free Approaches?

Author:

Richard I. Fisher

Richard I. Fisher
Search for other papers by Richard I. Fisher in
Current site
Google Scholar
PubMed

View More View Less

Volume/Issue:: Volume 17: Issue 11.5

Online Publication Date:: Nov 2019

DOI:: https://doi.org/10.6004/jnccn.2019.5038

Restricted access

Get Citation Alerts

Over the past several decades, tremendous progress has been made in the treatment of follicular lymphoma. The addition of rituximab to chemotherapy led to significant improvements in survival in the 1990s. Current standard of care in advanced-stage, previously untreated follicular lymphoma is rituximab plus chemotherapy, sometimes followed by rituximab maintenance. Now, as more research is conducted in the field of chemotherapy-free treatment, Dr. Richard I. Fisher discussed the importance of carefully constructed phase II or III trials at the NCCN 2019 Annual Congress: Hematologic Malignancies. He maintained that a nonchemotherapy treatment regimen comprising rituximab + lenalidomide can be considered in carefully selected patients, and that it is currently the only chemotherapy-free treatment that should be recommended.

Disclosures: Dr. Fisher has disclosed that he receives consulting fees from Celgene Corporation and PRIME.

Correspondence: Richard I. Fisher, MD, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111. Email: richard.fisher@fccc.edu

Print
Save
Cite
Email this content

Share Link

Copy this link, or click below to email it to a friend
Email this content
or copy the link directly:

https://jnccn.org/abstract/journals/jnccn/17/11.5/article-p1414.xml
The link was not copied. Your current browser may not support copying via this button.

Link copied successfully